We previously demonstrated that AKT2, a member of protein kinase B family, is activated by a number of growth factors via Ras and PI 3-kinase signaling pathways. Here, we report the frequent activation of AKT2 in human primary ovarian cancer and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase (PI 3-kinase)/Akt pathway. In vitro AKT2 kinase assay analyses in 91 ovarian cancer specimens revealed elevated levels of AKT2 activity (43-fold) in 33 cases (36.3%). The majority of tumors displaying activated AKT2 were high grade and stages III and IV. Immunostaining and Western blot analyses using a phospho-ser-473 Akt antibody that detects the activated form of AKT2 (AKT2 phosphorylated at serine-474) con®rmed the frequent activation of AKT2 in ovarian cancer specimens. Phosphorylated AKT2 in tumor specimens localized to the cell membrane and cytoplasm but not the nucleus. To address the mechanism of AKT2 activation, we measured in vitro PI 3-kinase activity in 43 ovarian cancer specimens, including the 33 cases displaying elevated AKT2 activation. High levels of PI 3-kinase activity were observed in 20 cases, 15 of which also exhibited AKT2 activation. The remaining ®ve cases displayed elevated AKT1 activation. Among the cases with elevated AKT2, but not PI 3-kinase activity (18 cases), three showed down-regulation of PTEN protein expression. Inhibition of PI 3-kinase/AKT2 by wortmannin or LY294002 induces apoptosis in ovarian cancer cells exhibiting activation of the PI 3-kinase/AKT2 pathway. These ®ndings demonstrate for the ®rst time that activation of AKT2 is a common occurrence in human ovarian cancer and that PI 3-kinase/Akt pathway may be an important target for ovarian cancer intervention.
We previously demonstrated that AKT2, a member of protein kinase B family, is activated by a number of growth factors via Ras and PI 3-kinase signaling pathways. Here, we report the frequent activation of AKT2 in human primary ovarian cancer and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase (PI 3-kinase)/Akt pathway. In vitro AKT2 kinase assay analyses in 91 ovarian cancer specimens revealed elevated levels of AKT2 activity (43-fold) in 33 cases (36.3%). The majority of tumors displaying activated AKT2 were high grade and stages III and IV. Immunostaining and Western blot analyses using a phospho-ser-473 Akt antibody that detects the activated form of AKT2 (AKT2 phosphorylated at serine-474) con®rmed the frequent activation of AKT2 in ovarian cancer specimens. Phosphorylated AKT2 in tumor specimens localized to the cell membrane and cytoplasm but not the nucleus. To address the mechanism of AKT2 activation, we measured in vitro PI 3-kinase activity in 43 ovarian cancer specimens, including the 33 cases displaying elevated AKT2 activation. High levels of PI 3-kinase activity were observed in 20 cases, 15 of which also exhibited AKT2 activation. The remaining ®ve cases displayed elevated AKT1 activation. Among the cases with elevated AKT2, but not PI 3-kinase activity (18 cases), three showed down-regulation of PTEN protein expression. Inhibition of PI 3-kinase/AKT2 by wortmannin or LY294002 induces apoptosis in ovarian cancer cells exhibiting activation of the PI 3-kinase/AKT2 pathway. These ®ndings demonstrate for the ®rst time that activation of AKT2 is a common occurrence in human ovarian cancer and that PI 3-kinase/Akt pathway may be an important target for ovarian cancer intervention. Oncogene (2000) 19, 2324 ± 2330.
Keywords: Akt; PI 3-kinase; signal transduction; ovarian cancer Akt/PKB represents a subfamily of the serine/threonine protein kinases (Bellacosa et al., 1991; Jones et al., 1991a, b; Cheng et al., 1992; Konishi et al., 1995; Nakatani et al., 1999) . Three members of this family, AKT1/PKBa, AKT2/PKBb and AKT3/PKBg have been identi®ed. Akt is activated by a variety of stimuli, including growth factors, protein phosphatase inhibitors, and stress (Franke et al., 1995; Burgering et al., 1995; Shaw et al., 1998; Liu et al., 1998) . Activation of Akt and AKT2 by growth factor is mediated by PI 3-kinase (Franke et al., 1995; Meier et al., 1997; Liu et al., 1998) . Active Ras and Src have also shown to activate Akt and AKT2 and this activation is blocked by wortmannin, a PI 3-kinase inhibitor, indicating that Ras and Src also mediate the activation of Akt and AKT2 and are located upstream of PI 3-kinase (Datta et al., 1996; Liu et al., 1998) . Several lines of evidence suggest that PI 3-kinase regulates Akt activation through the following mechanism: the product of PI 3-kinase, phosphatidylinositol-3,4,5-trisphosphate, binds to the pleckstrin homology (PH) domain of Akt after growth factor stimulation, resulting in recruitment of Akt to the cell membrane. A conformational change of Akt follows, which allows residues Thr-308 and Ser-473 to be phosphorylated by upstream kinases, PDK-1 and PDK2 or ILK, respectively Delcommenne et al., 1998) . Several downstream targets of Akt, each of which contains the Akt phosphorylation consensus sequence R-X-R-X-X-S/T-F/L, have been identi®ed , pointing to the possible mechanisms by which Akt promotes cell survival and blocks apoptosis. One such target is GSK3. Akt phosphorylates GSK3 and leads to inactivation of GSK3, accumulation of bcatenin, and activation of Myc transcription. There is also evidences that Akt phosphorylates the proapoptotic proteins BAD, caspase-9 and transcription factor FKHRL1, resulting in reduced binding of BAD to Bcl-X L and inhibition of caspase-9 protease activity and Fas ligand transcription (Datta et al., 1997; del Peso et al., 1997; Cardone et al., 1998; Brunet et al., 1999) . Recent studies demonstrated that PTEN/MMAC1 tumor suppressor and SHIP, tyrosine and inositol phosphatases, dephosphorylate phosphatidylinositol -3, 4, 5 -triphosphate, thus, inhibiting the PI 3-kinase/Akt signaling pathway (Stambolic et al., 1998; Aman et al., 1998) .
Several members within the PI 3-kinase/Akt pathway, including PI 3-kinase, PTEN, AKT2, and bcatenin, have been implicated in human neoplasms . Overexpression of p85, the regulatory subunit, or p110, the catalytic subunit, of PI 3-kinase is able to transform cells (Chang et al., 1997; Jimenez et al., 1998) . Alterations of PI 3-kinase have also been detected in a number of human malignancies (Shayesteh et al., 1999; Phillips et al., 1998) . Mutation and/or down regulation of the Pten are frequently observed in endometrial carcinoma, glioblastoma, breast cancer and prostate carcinoma (Stambolic et al., 1998) . We and others have previously demonstrated alterations of AKT2 at DNA, mRNA and/or protein level in several types of human malignancy (Cheng et al., 1992 (Cheng et al., , 1996 Bellacosa et al., 1995; Ruggeri et al., 1998) . In particular, ampli®cation/overexpression of AKT2 has been detected in 10 ± 20% of ovarian carcinomas and pancreatic cancers. However, increased activation of AKT2 in human tumors has not been demonstrated previously.
In this report, we show that kinase activity of AKT2 is frequently elevated in human primary ovarian tumor. In vitro AKT2 kinase assays were performed in 91 primary human ovarian tumors, including 34 serous cystadenocarcinomas, four mucinous cystadenocarcinomas, 25 papillary serous adenocarcinomas, 10 endometrioid adenocarcinomas, two borderline tumors, ®ve granulosa cell tumors and 11 other rare types of tumors including adenosarcoma, thecoma, ®broma, and mesodermal mixed tumor. Lysates from tumor specimens containing equivalent amounts of protein were precleared and incubated with anti-AKT2 antibody, which speci®cally reacts with AKT2, in the presence of protein-A : protein-G beads. The immunoprecipitates were subjected to in vitro kinase assay using Histone H2B as the substrate. In vitro kinase assays were carried out three times for each specimen. Average reading of the kinase activity threefold higher than that in normal ovarian tissue was considered elevated AKT2 activity. The results revealed an elevated level of AKT2 kinase in 33 specimens (36.3%), including 15 serous cystadenocarcinomas (44%), 14 papillary serous adenocarcinomas (56%) and four other types of tumor including one adenosarcoma, two malignant clear cell tumors, and one mixed mullerian tumor. Examples of AKT2 kinase activity in ovarian cancer are shown in Figure 1 . Interestingly, the majority of cases exhibiting activation of AKT2 were serous adenocarcinomas (29/33). None of endometrioid, borderline, mucinous, and granulosa cell tumors exhibited elevated AKT2 kinase activity.
To examine whether variations in AKT2 protein expression level contributes to the level of AKT2 activity observed in ovarian tumor specimens, we analysed its expression by Western blot analyses using a speci®c anti-AKT2 antibody. A high level of AKT2 protein was detected in 42 of 91 cases (46%). The 33 cases that exhibited elevated AKT2 activity displayed variable levels of AKT2 protein, 25 of which expressed AKT2 at high or moderate levels ( Figure 1 and Table  1 ). These results were also con®rmed by immunohistochemical staining of the tumor tissue section (data not shown).
Previous studies demonstrated that phosphorylation of Thr-308 and Ser-473 of Akt1 is required for its full activation. Upon stimulation of PI 3-kinase by growth factors, Akt1 becomes phosphorylated at these two residues. It has been shown that AKT2 is activated by phosphorylation of the equivalent residues (Thr-309 and Ser-474) . The homology of Akt1 to AKT2 and AKT3 is 90.4% and 87.8% at the amino acid level, respectively (Cheng et al., 1992; Nakatani et al., 1999) , and the sequence of the serine-473 phosphorylation site of Akt1 is highly conserved in AKT2 and AKT3 ( Figure 2a ).
Anti-phospho-Ser473 Akt antibody has widely been used to identify Akt1 activation. To determine whether such an antibody can be used to detect AKT2 activation in ovarian cancer specimens by Western blotting and immunostaining, we tested whether a phospho-Ser473 Akt antibody reacted with phosphorylated AKT2. HA-AKT2 expression construct was transfected to COS-7 cells. After serum-starvation overnight and IGF-1 stimulation for 10 min, HA-AKT2 was immunoprecipitated with anti-HA monoclonal antibody. The immunoprecipitates were separated by SDS ± PAGE and probed with phosphoSer473 Akt antibody. The results showed that the antibody against phospho-Ser473 Akt strongly reacted with phospho-Ser 474 of AKT2 ( Figure 2b ).
We next examined AKT2 phosphorylation by Western blot analyses of AKT2 immunoprecipitates with phospho-Ser473 Akt antibody in 43 ovarian tumor specimens including the 33 cases with and 10 cases without elevated AKT2 kinase activity. A sheep anti-AKT2 antibody was used to incubate with equal amount of protein from ovarian tumor lysates in the presence of protein-A and protein-G agarose. After extensive wash with the lysis buer, the AKT2 immunoprecipitates were separated by SDS ± PAGE and the blots were probed with the rabbit polyclonal phospho-Ser473 Akt antibody (New England Biolab). Phosphorylated AKT2 was detected only in ovarian tumors with elevated AKT2 kinase activity; for example, see data from tumors T2, 5, 7, 10 and 13, which exhibit high AKT2 kinase activity, shown in Figure 2c . These data con®rm the results obtained from in vitro AKT2 kinase assay and indicate that AKT2 activity is regulated by phosphorylation at Ser474 in human primary tumors. (Liu et al., 1998) . Lysates were incubated with anti-AKT2 antibody in the presence of protein A-protein G (2 : 1) agarose beads for 2 h at 48C. Following extensive wash, immunoprecipitates were subjected to in vitro kinase assay (Liu et al., 1998) . Histone H 2 B was used as the exogenous substrate. Each experiment was repeated three times. The relative amounts of incorporated radioactivity were determined by autoradiography and quantitated with a Phosphorimager. AKT2 is activated in cases T2, T5, T7, T10, T13, and T15. Middle panel: Western blot analysis of AKT2 expression in ovarian carcinoma. The blot was reprobed with anti-b-actin antibody (Bottom panel) Due to the fact that stromal tissues approximately account for 20*30% of the tumor specimens used in this study, we examined whether activation of AKT2 is derived from tumor cells or stromal tissues by immunostaining the tumor paran sections with phospho-Ser473 Akt antibody. We ®rst tested if the phospho-Ser473 Akt antibody is capable of recognizing phosphorylated AKT2 by immunohistochemistry. Cell paran blocks were prepared from serumstarved and serum-starved/EGF-stimulated OVCAR-3 cells that overexpress AKT2 (Cheng et al., 1992) . Phospho-Ser473 antibody was used to detect phosphorylated AKT2 in the section from these blocks by immunohistochemical means. Strong positive staining was observed in EGF-stimulated but not serum-starved OVCAR-3 cells (panel 1*2 in Figure  3a ). Phosphorylation status of AKT2 in these cells was con®rmed by Western blot analysis with phospho-S473 Akt antibody (lanes 1 and 2 in Figure  3b) .
Immunostaining of the tumor paran sections with phospho-Ser473 antibody was performed in 43 ovarian cancer specimens including 33 cases exhibiting elevated AKT2 kinase activity and 10 cases without AKT2 activation. Positive staining of tumor cells was observed in 38 cases including 33 with and ®ve without AKT2 activation detected by in vitro kinase assay and Western blot analyses. The fact that phospho-Ser473 Akt antibody recognizes Akt1, AKT2 and possible AKT3 suggests that activation of AKT1 or AKT3 present in these ®ve cases, which may be due to dierent expression levels of three isoforms of Akt. Immunohistochemical staining of paran tissue sections with anti-AKT1 and -AKT2 antibodies revealed that AKT1 but not AKT2 is highly expressed in these ®ve specimens (Figure 3c ). Moreover, in vitro kinase assay showed that AKT1 kinase activity is elevated in these specimens (Figure 3d , and also see case 8 in Figures 1 and 4) . Unfortunately, no good AKT3 antibody is commercially available at present time, therefore, we could not determine if AKT3 protein is altered in these specimens. Strikingly, phosphorylated Akt localizes to cytoplasm and cell membrane. Even in EGF-stimulated OVCAR-3 cells, activated Akt stays in cytoplasm and cell membrane. No nuclear staining was observed (panels 2 and 4 of Figure 3a) .
One mechanism that could result in an increased activation of AKT2 is an up-regulation of PI 3-kinase. PI 3-kinase is a heterodimer composed of a p85-regulatory and a p110-catalytic subunit. Three isoforms of p85 and p110 have been cloned, namely p85a, p85b, p85g, p110a, p110b and p100g. Recent studies demonstrated transforming activity of p110 and p85 and frequent activation PI 3-kinase in colon and ovarian carcinoma cell lines (Chang et al., 1997; Jimenez et al., 1998; Shayesteh et al., 1999; Phillips et al., 1998) . To examine PI 3-kinase activity in tumor tissues, immunoprecipitation with a pan-p85 speci®c antibody was performed in 43 ovarian cancer cases, including 33 with and 10 without AKT2 activation (Klippel et al., 1993) . Following extensive wash, the immunoprecipitates were subjected to in vitro PI 3-kinase assay using L-aphosphatidylinositol-4,5-bis phosphate (PI-4,5-P 2 ) or La-phosphatidylinositol-4-phosphate (PI-4-P 1 ) as substrates. The conversion of PI-4,5-P 2 to PI-3,4,5-P 3 or PI-4-P 1 to PI-3,4-P 2 was determined by autoradiography and quantitated by Phosphorimager. Elevated PI 3-kinase activity was detected in 20 ovarian cancer specimens, 15 of which exhibited AKT2 activation and the other ®ve displayed AKT1 activation (Figures 3  and 4 ). Since p110a has been shown to be overexpressed and activated in ovarian cancer cell lines (Shayesteh et al., 1999) , we examined whether increased levels of activity observed in our primary ovarian tumor specimens resulted from increased levels of p110 expression. PI 3-kinase was immunoprecipitated with an anti-p85 antibody from equal amounts of tumor extract protein. The immunoprecipitates were then separated on a SDS ± PAGE, transferred to a membrane and probed with a speci®c anti-p110a antibody. Figure 4 shows a correlation between p110a expression levels and PI 3-kinase activity in tumor samples. Quantitative analysis by a BioImager (Genomic Solutions Inc.) revealed that the levels of p110a expression in the tumors with PI 3-kinase activation are 2*4-folds higher than that in the specimens showing no elevated PI 3-kinase, except T12 that exhibited high level of p110a protein but no signi®cant PI 3-kinase activation. These data indicate that increases of PI 3-kinase activity contribute to AKT activation in human primary ovarian carcinoma. Another mechanism shown to result in activation of Akt is inactivation or loss of expression of PTEN. Inactivating mutations of the Pten tumor suppressor gene, on chromosome 10q23, have been described in prostate, endometrial and ovarian endometrioid carcinomas (Obata et al., 1998) . Previous studies have also observed down-regulation of PTEN protein in prostate cancer (Wu et al., 1998; McMenamin et al., 1999) . Therefore, we examined whether down-regulation of PTEN is associated with AKT2 activation in ovarian cancer. We analysed PTEN expression in 18 ovarian cancer specimens displaying elevated AKT2 activity by Western blot. A large reduction in PTEN protein expression was observed in three cases, two of which were serous cystadenocarcinomas and one was a papillary serous adenocarcinoma ( Figure 5 ). In these cases, we did not detect either mutations or low mRNA level of the Pten gene (data not shown). Interestingly, we failed to observe elevated AKT2 kinase activity in 10 endometrioid adenocarcinomas examined, even though PTEN mutations have most frequently been detected in this type of ovarian tumor. These results suggest that down-regulation of PTEN protein expression, either by translational or posttranslational changes, may be a factor in elevating AKT2 activation in non-endometrioid ovarian cancer.
We next examined the relationships between activation of AKT2 and tumor stage and grade. The results are presented in Tables 1 and 2 . High levels of AKT2 activity were seen in stages III and IV (33/68, 48.5%) but not stages I and II. The incidence of AKT2 activation increased with increasing grade. High levels of AKT2 kinase activity were detected in 52.9% of grades III and IV tumors, whereas activation of AKT2 was observed in only 15% of grades I and II tumors. These data indicate that activation of AKT2 in ovarian carcinoma is associated with late stage and high-grade tumors, and suggest an increase in the activation of AKT2 kinase as ovarian cancer progresses to a more aggressive phenotype.
It has been shown that Akt induces cell survival and suppresses the apoptotic death of a number of cell types induced by a variety of stimuli, including growth factor Figure 3 Phosphorylated Akt detected by immunostaining localizes to cell membrane and cytoplasm of ovarian tumor cells. The paran sections were subjected to antigen retrieval by boiling in a microwave and then incubated in a blocking solution and an avidin/biotin blocking kit (Vector). The primary antibody to phospho-S473 Akt (Upstate Biotechnology) was applied at a dilution of 1 : 200. After incubation, the slides were treated with biotinylated rabbit anti-goat immunoglobulin and streptavidin and biotinylated alkaline phosphatase. (a) Sections of paran blocks prepared from serum-starved (1), EGF-stimulated OVCAR3 cells (2) and 2 primary ovarian carcinoma specimens (3*4) were stained with phospho-Ser473 antibody. No staining was observed in serum starved OVCAR3 cells and a specimen without elevated AKT2 kinase activity (1 and 3), whereas strong reaction with phospho-Ser473 antibody is seen in EGF-stimulated OVCAR3 cells and a tumor specimen exhibiting AKT2 activation. (b) Western blot analysis of the AKT2 immunoprecipitates from the cells and the tissues that are used for immunostaining in Figure 3a withdrawal, cell-cycle discordance and loss of cell adhesion. To assess the in¯uence of PI 3-kinase/AKT activation on the cell growth of human ovarian cancer cells, we have performed in vitro kinase assay and observed activation of AKT2 and PI 3-kinase in 2 of 5 ovarian cancer cell lines (Figure 6a ). If PI 3-kinase/Akt pathway is crucial for survival in such ovarian tumor cells, blocking the activity of PI 3-kinase/Akt is expected to inhibit the cell growth and/or induce apoptosis. To test this hypothesis, three ovarian cancer cell lines with or without PI 3-kinase/AKT2 activation were treated with PI 3-kinase inhibitors, wortmannin (200 nM) or LY294002 (40 mM), or vehicle (DMSO), for 12 h in a medium containing 1% fetal calf serum. Those cell lines exhibiting elevated levels of PI 3-kinase and AKT2 activity underwent apoptosis after treatment with wortmannin or LY294002, whereas no apoptosis was detected in the cell line (e.g., A2780) without PI 3-kinase/ AKT2 activation (Figure 6 ).
In this study, we have demonstrated frequent activation of AKT2 kinase in human primary ovarian cancer by in vitro kinase assay, Western blot and immunohistochemical staining. Phosphorylated AKT2 has a cell membrane and cytoplasmic but not nuclear localization. Increased PI 3-kinase activation is observed in the majority of cases displaying AKT2 activation. High levels of AKT2 protein expression are also frequently detected in ovarian cancer specimens. Down regulation of PTEN was observed in nonendometrioid ovarian tumors, which may contribute to AKT2 activation. Moreover, activation of AKT2 is associated with high grade and late stage ovarian cancer and direct inhibition of PI 3-kinase/Akt pathway induces apoptosis in ovarian cancer cell lines exhibiting activation of PI 3-kinase and AKT2.
Previous studies showed that alteration of oncogene could occur at DNA, mRNA, protein, or enzymatic level. An extensive review of the topic indicates that the frequency of oncogene ampli®cation in primary tumors is about 5 ± 38%, depending on tumor type, stage, and grade as well as the individual gene (Brison, 1993) . The incidence of overexpression of some oncogenes in certain tumors is even higher due to the mechanism of enhanced transcription or translation, and mRNA or protein stabilization (Brison, 1993; Devilee and Cornelisse, 1994; Berns et al., 1995) . We and others have previously shown alterations of AKT2 at DNA and mRNA levels in *12% and *25% of ovarian carcinoma, respectively (Cheng et al., 1992; Bellacosa et al., 1995) . In this study, we demonstrate activation of AKT2 kinase in 36.3% of primary ovarian tumors with highest frequency (49%) in serous adenocarcinomas. Moreover, we have also observed overexpression of AKT2 protein in 46% of ovarian cancer specimens examined. These data, as compared to AKT2 alteration at DNA and RNA levels, indicate that activation and overexpression of AKT2 protein by aberrant translational regulation and posttranslational modi®cation of AKT2 is a more common occurrence in human ovarian cancer. The fact that overexpression of wild type AKT2 in NIH3T3 cells results in malignant transformation (Cheng et al., 1997) suggests that activation and overexpression of AKT2 in human ovarian carcinoma could play an important role in the development of this malignancy.
Several studies demonstrated that ectopically expressed Akt1 and AKT2, following growth factor stimulation, initially locates to cell membrane and then translocates to the nucleus Meier et al., 1997) . This is thought to allow Akt mediated phosphorylation of nuclear transcription factors, such as Forkhead proteins and CREB (Brunet et al., 1999; Kops et al., 1999; Du and Montminy, 1998) . In contrast, in primary ovarian tumor specimens examined, we found that phosphorylated AKT2 localizes to cell membrane and cytoplasm but not the nucleus. Moreover, activated endogenous AKT2 in AKT2-overexpressing OVCAR cells was also localized to cell membrane and cytoplasm only. These con¯icting observations may be due to the fact that ectopic overexpression of Akt aects its subcellular localization.
We and others have previously documented that AKT2 is a downstream target of PI 3-kinase and is activated by a number of growth factors (Meier et al., Figure 4 Activation of PI 3-kinase in human ovarian cancer specimens. In vitro PI 3-kinase assay of the anti-p85 immunoprecipitates from 12 frozen ovarian cancer specimens. The tumor tissue lysates were immunoprecipitated with pan-p85 antibody (Santa Cruz). Following wash, the presence of PI 3-kinase activity in immunoprecipitates was determined by incubating the beads with reaction buer. Phospholipids were extracted and separated by thin-layer chromatography as previously described (Jiang et al., 2000) . The conversion of PI-4,5-P 2 to PI 3-phosphate and PI-4-P1 to PI-3,4-P 2 was determined by autoradiography and quantitated by using a Phosphorimager. Elevated levels of PI 3-kinase activity (top panel) and p110a protein (middle panel) are detected in cases 2, 7, 8, 12, and 13. The expression levels of p110a are quanti®ed by a BioImager. The density of each band is indicated at the bottom 1997; Liu et al., 1998) . Active Ras and Src signi®cantly induce AKT2 activation (Liu et al., 1998) . Recent studies have shown that Akt activity is regulated by PTEN, which reduces intracellular levels of PI-3,4,5,-P 3 in cells by converting PI-3,4,5-P 3 to PI-4,5-P 2 and, thus, inhibits PI 3-kinase/Akt signaling pathway (Stambolic et al, 1998; Aman et al., 1998) . Therefore, AKT2 activation in human ovarian cancer may result from; (a) PI 3-kinase activation; (b) Pten mutation; (c) overexpression of AKT2; (d) alterations of growth factor receptor, such as overexpression or mutation of EGFR; (e) ras mutation; or (f) active mutation of the AKT2 gene. In this report, we document that nearly half of cases with AKT2 activation (15/33) display PI 3-kinase activation, which supports a recent observation of PI 3-kinase activation in ovarian cancer cell lines (Shayesteh et al., 1999) . Down regulation of PTEN was detected in three non-endometrioid cases of ovarian tumors. Interestingly, we did not observe either lack of PTEN expression or AKT2 activation in all 10 endometrioid adenocarcinomas examined, implying that the Pten may not be mutated in these specimens.
We have also performed single strain conformation polymorphism analyses of the tumors carrying activated AKT2. No AKT2 mutation was observed. The cases exhibiting AKT2 activation express variable levels of AKT2 protein, suggesting that expression of AKT2 protein is required for activation of AKT2 in ovarian tumor. The fact that three members of Akt family are down stream targets of PI 3-kinase and are regulated by similar mechanism suggests that AKT1 and AKT3 may also be activated in human ovarian cancer. In this study, we focused on activation of AKT2 in primary ovarian cancer. However, we have shown activation of AKT1 and PI 3-kinase but not AKT2 in ®ve ovarian cancer specimens, which express high levels of AKT1 but very low levels of AKT2 (Figure 3) . Additional experiments to evaluate the signi®cance of this ®nding are in progress.
We have previously demonstrated that an activated Ras signi®cantly activates AKT2. We have also recently documented that farnesyltransferase inhibitor (FTI)-277, an anticancer drug blocking the posttranslational farnesylation of oncogenic Ras, inhibits PI 3-kinase and AKT2 activity and induces apoptosis in that Wortmannin blocks activity of PI 3-kinase and AKT2, and induces apoptosis in OVCAR3 and OVCAR8 cells. The cells were seeded into 60 mm dishes and grown for 24 h and then treated with wortmannin (200 nM) or LY294002 (40 mM) for 12 h. Apoptosis was determined by TdT-mediated dUTP nick end labeling (Tunel) using an in situ cell death detection kit (Boehringer). To detect DNA fragmentation, cellular DNA was prepared using the DNA kit (Qiagen). The DNA was analysed on 1.5% agarose gel and visualized by ethidium bromide staining AKT2 overexpressing cell lines (Jiang et al., 2000) . Overexpression of AKT2, but not Ras, sensitizes NIH3T3 cells to FTI-277. However, FTI-277 is not a direct inhibitor of PI 3-kinase and AKT2. In this study, we demonstrate that direct inhibition of PI 3-kinase/Akt pathway by wortmannin or LY294002 induces apoptosis in ovarian cancer cell lines with PI 3-kinase/AKT2 activation. Moreover, we have also shown that the majority of tumors with activated AKT2 are high grade and late stage. These data indicate that activation of PI 3-kinase/Akt may play a pivotal role in development of human ovarian cancer, especially in tumor progression, and that PI 3-kinase/ Akt pathway could be an important target for intervention of this malignancy. Future studies are required to de®ne the role of Akt activation in ovarian malignant transformation.
